346 related articles for article (PubMed ID: 22404722)
1. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.
Sasso M; Tengher-Barna I; Ziol M; Miette V; Fournier C; Sandrin L; Poupon R; Cardoso AC; Marcellin P; Douvin C; de Ledinghen V; Trinchet JC; Beaugrand M
J Viral Hepat; 2012 Apr; 19(4):244-53. PubMed ID: 22404722
[TBL] [Abstract][Full Text] [Related]
2. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?
Kumar M; Rastogi A; Singh T; Behari C; Gupta E; Garg H; Kumar R; Bhatia V; Sarin SK
J Gastroenterol Hepatol; 2013 Jul; 28(7):1194-201. PubMed ID: 23425053
[TBL] [Abstract][Full Text] [Related]
3. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.
Myers RP; Pollett A; Kirsch R; Pomier-Layrargues G; Beaton M; Levstik M; Duarte-Rojo A; Wong D; Crotty P; Elkashab M
Liver Int; 2012 Jul; 32(6):902-10. PubMed ID: 22435761
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
[TBL] [Abstract][Full Text] [Related]
5. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients.
Lupşor M; Badea R; Stefănescu H; Grigorescu M; Sparchez Z; Serban A; Branda H; Iancu S; Maniu A
J Gastrointestin Liver Dis; 2008 Jun; 17(2):155-63. PubMed ID: 18568136
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.
Ziol M; Handra-Luca A; Kettaneh A; Christidis C; Mal F; Kazemi F; de Lédinghen V; Marcellin P; Dhumeaux D; Trinchet JC; Beaugrand M
Hepatology; 2005 Jan; 41(1):48-54. PubMed ID: 15690481
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B.
Cardoso AC; Beaugrand M; de Ledinghen V; Douvin C; Poupon R; Trinchet JC; Ziol M; Bedossa P; Marcellin P
Ann Hepatol; 2015; 14(6):826-36. PubMed ID: 26436354
[TBL] [Abstract][Full Text] [Related]
8. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
Poynard T; de Ledinghen V; Zarski JP; Stanciu C; Munteanu M; Vergniol J; France J; Trifan A; Le Naour G; Vaillant JC; Ratziu V; Charlotte F;
J Hepatol; 2012 Mar; 56(3):541-8. PubMed ID: 21889468
[TBL] [Abstract][Full Text] [Related]
9. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
Chan WK; Nik Mustapha NR; Mahadeva S
J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
[TBL] [Abstract][Full Text] [Related]
10. How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound.
Carvalhana S; Leitão J; Alves AC; Bourbon M; Cortez-Pinto H
Liver Int; 2014 Jul; 34(6):e111-7. PubMed ID: 24034415
[TBL] [Abstract][Full Text] [Related]
11. Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
Mendes LC; Ferreira PA; Miotto N; Zanaga L; Lazarini MS; Gonçales ESL; Pedro MN; Gonçales FL; Stucchi RSB; Vigani AG
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):959-966. PubMed ID: 29727388
[TBL] [Abstract][Full Text] [Related]
12. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy.
Shi KQ; Tang JZ; Zhu XL; Ying L; Li DW; Gao J; Fang YX; Li GL; Song YJ; Deng ZJ; Wu JM; Tang KF
J Gastroenterol Hepatol; 2014 Jun; 29(6):1149-58. PubMed ID: 24476011
[TBL] [Abstract][Full Text] [Related]
13. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B.
Xu L; Lu W; Li P; Shen F; Mi YQ; Fan JG
Dig Liver Dis; 2017 Aug; 49(8):910-917. PubMed ID: 28433586
[TBL] [Abstract][Full Text] [Related]
14. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
Wong VW; Petta S; Hiriart JB; Cammà C; Wong GL; Marra F; Vergniol J; Chan AW; Tuttolomondo A; Merrouche W; Chan HL; Le Bail B; Arena U; Craxì A; de Lédinghen V
J Hepatol; 2017 Sep; 67(3):577-584. PubMed ID: 28506907
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).
Yoneda M; Yoneda M; Mawatari H; Fujita K; Endo H; Iida H; Nozaki Y; Yonemitsu K; Higurashi T; Takahashi H; Kobayashi N; Kirikoshi H; Abe Y; Inamori M; Kubota K; Saito S; Tamano M; Hiraishi H; Maeyama S; Yamaguchi N; Togo S; Nakajima A
Dig Liver Dis; 2008 May; 40(5):371-8. PubMed ID: 18083083
[TBL] [Abstract][Full Text] [Related]
16. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers.
Sánchez-Conde M; Montes-Ramírez ML; Miralles P; Alvarez JM; Bellón JM; Ramírez M; Arribas JR; Gutiérrez I; López JC; Cosín J; Alvarez E; González J; Berenguer J
J Viral Hepat; 2010 Apr; 17(4):280-6. PubMed ID: 19732322
[TBL] [Abstract][Full Text] [Related]
17. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
[TBL] [Abstract][Full Text] [Related]
18. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B.
Chan HL; Wong GL; Choi PC; Chan AW; Chim AM; Yiu KK; Chan FK; Sung JJ; Wong VW
J Viral Hepat; 2009 Jan; 16(1):36-44. PubMed ID: 18673426
[TBL] [Abstract][Full Text] [Related]
19. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
Friedrich-Rust M; Müller C; Winckler A; Kriener S; Herrmann E; Holtmeier J; Poynard T; Vogl TJ; Zeuzem S; Hammerstingl R; Sarrazin C
J Clin Gastroenterol; 2010 Jan; 44(1):58-65. PubMed ID: 19581812
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with controlled attenuation parameter (CAP).
Cardoso AC; Perez RM; de Figueiredo-Mendes C; Carvalho Leite N; Moraes-Coelho HS; Villela-Nogueira CA
J Viral Hepat; 2018 Nov; 25(11):1244-1250. PubMed ID: 29768686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
